Charles L. Bennett, MD, PhD, MPP

Ibrutinib has been selected for Medicare price negotiation under the Inflation Reduction Act. The authors summarize the House Oversight Committee investigation to be considered by CMS during the price negotiation process.

The authors review a House Oversight Committee investigation report on AbbVie’s practices pertaining to adalimumab (Humira) to shed light on broader pharmaceutical market dynamics hindering a competitive market.

Single-tablet regimens are associated with higher adherence rates, decreased hospitalizations, and a higher proportion of patients with undetectable viral load compared with multiple-tablet regimens in patients with HIV/AIDS.